{"id":554,"date":"2023-09-14T09:28:00","date_gmt":"2023-09-14T16:28:00","guid":{"rendered":"https:\/\/caam.tech\/?p=554"},"modified":"2023-09-14T01:26:51","modified_gmt":"2023-09-14T08:26:51","slug":"caamtech-ceo-to-present-at-acs-meeting","status":"publish","type":"post","link":"https:\/\/caam.tech\/caamtech-ceo-to-present-at-acs-meeting\/","title":{"rendered":"CaaMTech CEO to Present at ACS Meeting"},"content":{"rendered":"\n

CaaMTech<\/a> CEO, Dr. Andrew Chadeayne<\/a>, will give two presentations at the 2023 Rocky Mountain Regional Meeting of the American Chemical Society on September 16th. The first presentation will focus on CaaMTech\u2019s collaborative scientific work in the field of tryptamine prodrugs.  CaaMTech leads the scientific investigation of tryptamine prodrugs and has amassed a library of novel tryptamine prodrugs that may offer clinically-optimized advantages over naturally-occuring versions.  The second presentation will focus on the \u201centourage\u201d effects caused by combinations of compounds present in psychedelic organisms.  Largely ignored until recently, these entourage effects may differentiate natural psychedelic organisms from the single molecule therapeutics often developed as pharmaceutical products.<\/p>\n\n\n\n

The ACS was founded in 1876 at New York University and boasts more than 155,000 members. CaaMTech has published several psychedelic chemistry research papers in the American Chemical Society\u2019s peer-reviewed journals. Some of these research publications touch on the topic of Dr. Chadeayne\u2019s presentation: tryptamine prodrugs.  New data comparing the physical, in vitro<\/em>, and in vivo<\/em> properties of psilocybin with synthetic prodrug analogs will be discussed along with opportunities for using prodrugs as an improved delivery mechanism to optimize the therapeutic potential of psychedelics.<\/p>\n\n\n\n

\u201cIt is an honor to present, once again, to the esteemed chemists of The American Chemical Society,\u201d said Dr. Chadeayne of his upcoming presentation.  \u201cCaaMTech gave the only psychedelics presentation at the American Chemical Society\u2019s 2019 Fall Meeting. Having an entire symposium dedicated to the Chemistry of Psychedelics at this meeting reflects the chemistry community\u2019s growing interest in psychedelics.\u201d<\/p>\n\n\n\n

Tryptamine prodrugs have emerged as an area of significant focus in the development of psychedelics as pharmaceuticals.  Psilocybin, a prodrug of the psychedelic psilocin, has received \u201cBreakthrough Therapy\u201d designation from the FDA for treating depression.  COMPASS Pathways PLC is conducting Phase III studies with psilocybin for treatment resistant depression (TRD).  Recently, Abilify maker Otsuka Pharmaceutical entered into an agreement to buy Mindset Pharma and its psilocin prodrug MSP-1014.  CaaMTech has developed an extensive library of tryptamine prodrugs – including several psilocin prodrugs with improved properties compared to psilocybin.<\/p>\n\n\n\n

\u201cMagic\u201d mushrooms\u2019 best known component, psilocybin, is a prodrug of the potent 5-HT2A <\/sub>agonist and powerful psychedelic compound, psilocin. However, psilocybin co-exists in these mushrooms with other less-studied, structurally similar compounds whose roles and pharmacological properties are poorly understood.  The lack of scientific data pertaining to these \u201cminor alkaloids\u201d has resulted in considerable speculation about their properties. Some have pointed to evidence of these compounds contributing to an \u201cEntourage Effect\u201d when consumed via psychedelic organisms.  In an interview with Benzinga earlier this year, Filament CEO Benjamin Lightburn said, \u201c…there is a big difference between a natural extract of a magic mushroom and synthetic psilocybin just like in cannabis.\u201d<\/p>\n\n\n\n

The 2023 Rocky Mountain Regional Meeting of the American Chemical Society, hosted by the Wyoming Local Section of the American Chemical Society, will take place September 14-17 at the University of Wyoming Conference Center in Laramie, Wyoming. The meeting theme is \u201cChemistry on the Frontier: Exploring New Horizons in the Cowboy State.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"

The American Chemical Society will host the Chemistry of Psychedelics symposium at the 2023 Rocky Mountain Regional Meeting Sept. 14\u201317 the University of Wyoming<\/p>\n","protected":false},"author":5,"featured_media":79,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1,5],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/posts\/554"}],"collection":[{"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/comments?post=554"}],"version-history":[{"count":2,"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/posts\/554\/revisions"}],"predecessor-version":[{"id":557,"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/posts\/554\/revisions\/557"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/media\/79"}],"wp:attachment":[{"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/media?parent=554"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/categories?post=554"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/tags?post=554"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}